Lepu Medical Technology Co (300003) Q2 2024 earnings summary

Executive summary

• Operating income for H1 2024 was RMB 3.38 billion, with net profit attributable to shareholders at RMB 697 million, both declining year-over-year due to high base effects and policy impacts.

• The company remains a leader in cardiovascular medical devices, pharmaceuticals, and medical care solutions, emphasizing innovation and internationalization.

• Significant R&D progress in cardiovascular intervention, ophthalmology, dermatology, and AI-driven medical products, with several new products approved and in clinical trials.

• Overseas business income grew 2.57% year-over-year, with gross margin up 3.23 percentage points.

Financial highlights

• Operating revenue for H1 2024 was RMB 3.38 billion, down 21.33% year-over-year.

• Net profit attributable to shareholders was RMB 697 million, down 27.48% year-over-year; net profit after non-recurring items was RMB 647 million, down 28.48%.

• Net cash flow from operating activities was RMB 159 million, up 12.13% year-over-year.

• Total assets at period end were RMB 25.3 billion; net assets attributable to shareholders were RMB 15.89 billion.

• Weighted average ROE was 4.47%, down 1.92 percentage points year-over-year.

Outlook and guidance

• Pharmaceutical sector income, including APIs, is expected to stabilize for the year, with preparation sector income projected at RMB 1.5–1.6 billion.

• Channel inventory clearance in pharmaceuticals may last 1–2 quarters, with a slight rebound expected post-adjustment.

• Continued focus on innovative product commercialization and international market expansion.